Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2026)
Intellia Therapeutics (NTLA) reported EPS (Weighted Average and Diluted) of -$0.81 for Q1 2026, up 26.36% year-over-year from -$0.64 in Q1 2025, and up 1.22% on a QoQ basis from -$0.82 in Q4 2025.
Intellia Therapeutics (NTLA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.81 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 26.36% year-over-year to -$0.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.53 (up 32.38% YoY) and the FY2025 annual result came in at -$3.81, up 27.43% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.81 in Q1 2026 per NTLA's latest filing, from -$0.82 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.81 in Q1 2026 and bottomed at -$1.96 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.33 (2022), against an average of -$1.26.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) plunged 53.61%; it then surged 40.31% in 2023.
- Tracing NTLA's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.38 in 2022, then retreated by 5.8% to -$1.46 in 2023, then increased by 13.7% to -$1.26 in 2024, then soared by 34.92% to -$0.82 in 2025, then climbed by 1.22% to -$0.81 in 2026.
- Per Business Quant, the three latest NTLA EPS (Weighted Average and Diluted) figures stand at -$0.81 (Q1 2026), -$0.82 (Q4 2025), and -$0.92 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -0.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.81 |
| Dec 31, 2025 | -0.82 |
| Sep 30, 2025 | -0.92 |
| Jun 30, 2025 | -0.98 |
| Mar 31, 2025 | -1.10 |
| Dec 31, 2024 | -1.26 |
| Sep 30, 2024 | -1.34 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -1.12 |
| Dec 31, 2023 | -1.46 |
| Sep 30, 2023 | -1.38 |
| Jun 30, 2023 | -1.40 |
| Mar 31, 2023 | -1.17 |
| Dec 31, 2022 | -1.38 |
| Sep 30, 2022 | -1.49 |
| Jun 30, 2022 | -1.33 |
| Mar 31, 2022 | -1.96 |
| Dec 31, 2021 | -1.10 |
| Sep 30, 2021 | -0.97 |
| Jun 30, 2021 | -1.01 |
| Dec 31, 2020 | -0.75 |